51
|
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011; 471:513-7. [PMID: 21430779 PMCID: PMC3348545 DOI: 10.1038/nature09806] [Citation(s) in RCA: 406] [Impact Index Per Article: 31.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2010] [Accepted: 01/07/2011] [Indexed: 01/05/2023]
Abstract
The most common mutation in melanoma, BRAF(V600E), activates the BRAF serine/threonine kinase and causes excessive MAPK pathway activity1,2. BRAF(V600E)mutations are also present in benign melanocytic nevi3, highlighting the importance of additional genetic alterations in the genesis of malignant tumors. Such changes include recurrent copy number variations that result in the amplification of oncogenes4,5. For certain amplifications, the large number of genes in the interval has precluded an understanding of cooperating oncogenic events. Here, we have used a zebrafish melanoma model to test genes in a recurrently amplified region on chromosome 1 for the ability to cooperate with BRAF(V600E) and accelerate melanoma. SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was found to significantly accelerate melanoma formation in the zebrafish. Chromatin immunoprecipitation coupled with massively parallel DNA sequencing (ChIP-Seq) and gene expression analyses revealed target genes, including Hox genes, that are transcriptionally dysregulated in response to elevated SETDB1. Our studies establish SETDB1 as an oncogene in melanoma and underscore the role of chromatin factors in regulating tumorigenesis.
Collapse
|
52
|
Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, Baffa J, Hopkins E, Sol-Church K, Limongelli G, Digilio MC, Marino B, Innes AM, Aoki Y, Silberbach M, Delrue MA, White SM, Hamilton RM, O'Connor W, Grossfeld PD, Smoot LB, Padera RF, Gripp KW. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A 2011; 155A:486-507. [PMID: 21344638 DOI: 10.1002/ajmg.a.33857] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2010] [Accepted: 11/26/2010] [Indexed: 01/01/2023]
Abstract
Cardiovascular abnormalities are important features of Costello syndrome and other Ras/MAPK pathway syndromes ("RASopathies"). We conducted clinical, pathological and molecular analyses of 146 patients with an HRAS mutation including 61 enrolled in an ongoing longitudinal study and 85 from the literature. In our study, the most common (84%) HRAS mutation was p.G12S. A congenital heart defect (CHD) was present in 27 of 61 patients (44%), usually non-progressive valvar pulmonary stenosis. Hypertrophic cardiomyopathy (HCM), typically subaortic septal hypertrophy, was noted in 37 (61%), and 5 also had a CHD (14% of those with HCM). HCM was chronic or progressive in 14 (37%), stabilized in 10 (27%), and resolved in 5 (15%) patients with HCM; follow-up data was not available in 8 (22%). Atrial tachycardia occurred in 29 (48%). Valvar pulmonary stenosis rarely progressed and atrial septal defect was uncommon. Among those with HCM, the likelihood of progressing or remaining stable was similar (37%, 41% respectively). The observation of myocardial fiber disarray in 7 of 10 (70%) genotyped specimens with Costello syndrome is consistent with sarcomeric dysfunction. Multifocal atrial tachycardia may be distinctive for Costello syndrome. Potentially serious atrial tachycardia may present in the fetus, and may continue or worsen in about one-fourth of those with arrhythmia, but is generally self-limited in the remaining three-fourths of patients. Physicians should be aware of the potential for rapid development of severe HCM in infants with Costello syndrome, and the need for cardiovascular surveillance into adulthood as the natural history continues to be delineated.
Collapse
Affiliation(s)
- Angela E Lin
- Genetics Unit, MassGeneral Hospital for Children, Boston, Massachusetts, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Abstract
Zebrafish are an ideal model organism to research cancer. Zebrafish embryos and larvae are optically translucent, which has made imaging multiple processes in development and disease possible. When coupled with fluorescent imaging techniques, zebrafish are fast becoming a model of choice for following tumor formation. This is highlighted by recent studies using fluorescent proteins to image xenograft transplantation, neovascularization, growth responses to drug treatments, and self-renewal. Fluorescent labeled tumors can be generated in zebrafish by multiple methods including chemical mutagenesis, oncogene expression by mosaic or stable transgenesis, or genetic mutations that are predisposing to cancer. In this chapter, we highlight the studies that have employed fluorescence to follow critical aspects of tumorigenesis, with particular focus on providing methods for labeling, isolating, transplanting, and imaging fluorescently labeled tumors in zebrafish.
Collapse
Affiliation(s)
- Myron S Ignatius
- Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | | |
Collapse
|
54
|
Abstract
Rhabdomyosarcoma (RMS), an aggressive malignant neoplasm that shows features of skeletal muscle, is the most common soft tissue tumor of childhood. In children, the major subtypes are embryonal and alveolar. Although localized disease responds to a multimodal treatment, the prognosis for patients with high-risk features and metastasis remains dismal. Several in vivo models of RMS have been developed in mouse, human xenografts, zebrafish, and Drosophila to better understand the underlying mechanisms governing malignancy. The findings so far have indicated the potential role of skeletal muscle precursor cells in malignant transformation. To better understand histogenesis and different aspects of tumorigenesis in RMS, we have previously developed a robust zebrafish model of kRAS-induced RMS, which shares morphologic and immunophenotypic features with the human counterpart. Cross-species mircroarray comparisons confirm that conserved genetic pathways drive RMS growth. The ease for ex vivo manipulation allows the development of different transgenic and co-injection strategies to induce tumor formation in zebrafish. In contrast to other vertebrate model systems, the tumor onset in zebrafish is short, allowing for efficient study of different tumor processes including tumor growth, self-renewal, and maintenance.
Collapse
|
55
|
Abstract
Melanoma is the most deadly form of skin cancer and incidence continues to rise rapidly (Gray-Schopfer et al., 2007). Melanoma develops from melanocytes, the pigmented cells that color our skin, hair, and eyes. Fish also have melanocytes, among other pigment cell types, and the fish and human developmental programme are highly conserved (Kelsh, 2004). The first fish models of melanoma were established in Xiphophorus, and more recently, transgenic melanoma models in zebrafish and medaka have been developed (Meierjohann and Schartl, 2006; Patton et al., 2010; Schartl et al., 2010). In this Chapter, we describe the basic techniques to generate genetic, environmental, and transgenic models of melanoma, discuss diagnoses, and describe standard molecular analysis techniques.
Collapse
Affiliation(s)
- E Elizabeth Patton
- MRC Human Genetics Unit & Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK
| | | | | |
Collapse
|
56
|
Feng Y, Santoriello C, Mione M, Hurlstone A, Martin P. Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol 2010; 8:e1000562. [PMID: 21179501 PMCID: PMC3001901 DOI: 10.1371/journal.pbio.1000562] [Citation(s) in RCA: 162] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2010] [Accepted: 10/29/2010] [Indexed: 01/02/2023] Open
Abstract
It has not previously been possible to live image the earliest interactions between the host environment and oncogene-transformed cells as they initiate formation of cancers within an organism. Here we take advantage of the translucency of zebrafish larvae to observe the host innate immune cell response as oncogene-transformed melanoblasts and goblet cells multiply within the larval skin. Our studies indicate activation of leukocytes at very early stages in larvae carrying a transformed cell burden. Locally, we see recruitment of neutrophils and macrophages by 48 h post-fertilization, when transformed cells are still only singletons or doublets, and soon after this we see intimate associations between immune and transformed cells and frequent examples of cytoplasmic tethers linking the two cell types, as well as engulfment of transformed cells by both neutrophils and macrophages. We show that a major component of the signal drawing inflammatory cells to oncogenic HRAS(G12V)-transformed cells is H(2)O(2), which is also a key damage cue responsible for recruiting neutrophils to a wound. Our short-term blocking experiments show that preventing recruitment of immune cells at these early stages results in reduced growth of transformed cell clones and suggests that immune cells may provide a source of trophic support to the transformed cells just as they do at a site of tissue repair. These parallels between the inflammatory responses to transformed cells and to wounds reinforce the suggestion by others that cancers resemble non-healing wounds.
Collapse
Affiliation(s)
- Yi Feng
- Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
- Department of Physiology and Pharmacology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
| | | | - Marina Mione
- IFOM, the FIRC Institute of Molecular Oncology Foundation, Milan, Italy
| | - Adam Hurlstone
- Faculty of Life Sciences, The University of Manchester, Manchester, United Kingdom
| | - Paul Martin
- Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
- Department of Physiology and Pharmacology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
| |
Collapse
|
57
|
Abstract
Almost half a century after the first reports describing the limited replicative potential of primary cells in culture, there is now overwhelming evidence for the existence of "cellular senescence" in vivo. It is being recognized as a critical feature of mammalian cells to suppress tumorigenesis, acting alongside cell death programs. Here, we review the various features of cellular senescence and discuss their contribution to tumor suppression. Additionally, we highlight the power and limitations of the biomarkers currently used to identify senescent cells in vitro and in vivo.
Collapse
Affiliation(s)
- Thomas Kuilman
- Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|
58
|
Abstract
For the last three decades significant parts of national science budgets, and international and private funding worldwide, have been dedicated to cancer research. This has resulted in a number of important scientific findings. Studies in tissue culture have multiplied our knowledge of cancer cell pathophysiology, mechanisms of transformation and strategies of survival of cancer cells, revealing therapeutically exploitable differences to normal cells. Rodent animal models have provided important insights on the developmental biology of cancer cells and on host responses to the transformed cells. However, the rate of death from some malignancies is still high, and the incidence of cancer is increasing in the western hemisphere. Alternative animal models are needed, where cancer cell biology, developmental biology and treatment can be studied in an integrated way. The zebrafish offers a number of features, such as its rapid development, tractable genetics, suitability for in vivo imaging and chemical screening, that make it an attractive model to cancer researchers. This Primer will provide a synopsis of the different cancer models generated by the zebrafish community to date. It will discuss the use of these models to further our understanding of the mechanisms of cancer development, and to promote drug discovery. The article was inspired by a workshop on the topic held in July 2009 in Spoleto, Italy, where a number of new zebrafish cancer models were presented. The overarching goal of the article is aimed at raising the awareness of basic researchers, as well as clinicians, to the versatility of this emerging alternative animal model of cancer.
Collapse
Affiliation(s)
- Marina C Mione
- IFOM Foundation - FIRC Institute of Molecular Oncology Foundation, via Adamello, Milan, Italy.
| | | |
Collapse
|
59
|
Abstract
Experimental animal models are extremely valuable for the study of human diseases, especially those with underlying genetic components. The exploitation of various animal models, from fruitflies to mice, has led to major advances in our understanding of the etiologies of many diseases, including cancer. Cutaneous malignant melanoma is a form of cancer for which both environmental insult (i.e., UV) and hereditary predisposition are major causative factors. Fish melanoma models have been used in studies of both spontaneous and induced melanoma formation. Genetic hybrids between platyfish and swordtails, different species of the genus Xiphophorus, have been studied since the 1920s to identify genetic determinants of pigmentation and melanoma formation. Recently, transgenesis has been used to develop zebrafish and medaka models for melanoma research. This review will provide a historical perspective on the use of fish models in melanoma research, and an updated summary of current and prospective studies using these unique experimental systems.
Collapse
Affiliation(s)
- E Elizabeth Patton
- Institute for Genetics and Molecular Medicine, MRC Human Genetics Unit and Division of Cancer Research, The University of Edinburgh, Edinburgh, UK.
| | | | | |
Collapse
|
60
|
Donnini S, Solito R, Cetti E, Corti F, Giachetti A, Carra S, Beltrame M, Cotelli F, Ziche M. Aß peptides accelerate the senescence of endothelial cells
in vitro
and
in vivo
, impairing angiogenesis. FASEB J 2010; 24:2385-95. [DOI: 10.1096/fj.09-146456] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Sandra Donnini
- Department of Molecular BiologyUniversity of SienaSienaItaly
| | | | - Elisa Cetti
- Department of Molecular BiologyUniversity of SienaSienaItaly
| | - Federico Corti
- Department of Molecular BiologyUniversity of SienaSienaItaly
| | | | - Silvia Carra
- Department of BiologyUniversita degli Studi di MilanoMilanItaly
| | - Monica Beltrame
- Department of Biomolecular Sciences and BiotechnologyUniversita degli Studi di MilanoMilanItaly
| | - Franco Cotelli
- Department of BiologyUniversita degli Studi di MilanoMilanItaly
| | - Marina Ziche
- Department of Molecular BiologyUniversity of SienaSienaItaly
| |
Collapse
|
61
|
Abstract
The importance of cellular senescence, which is a stress response that stably blocks proliferation, is increasingly being recognized. Senescence is prevalent in pre-malignant tumours, and progression to malignancy requires evading senescence. Malignant tumours, however, may still undergo senescence owing to interventions that restore tumour suppressor function or inactivate oncogenes. Senescent tumour cells can be cleared by immune cells, which may result in efficient tumour regression. Standard chemotherapy also has the potential to induce senescence, which may partly underlie its therapeutic activity. Although these concepts are well supported in mouse models, translating them to clinical oncology remains a challenge.
Collapse
|
62
|
Anelli V, Santoriello C, Distel M, Köster RW, Ciccarelli FD, Mione M. Global Repression of Cancer Gene Expression in a Zebrafish Model of Melanoma Is Linked to Epigenetic Regulation. Zebrafish 2009; 6:417-24. [DOI: 10.1089/zeb.2009.0612] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Viviana Anelli
- IFOM Foundation—FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy
| | - Cristina Santoriello
- IFOM Foundation—FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy
| | - Martin Distel
- Institute of Developmental Genetics, Helmholtz Center Munich, Munich, Germany
| | - Reinhard W. Köster
- Institute of Developmental Genetics, Helmholtz Center Munich, Munich, Germany
| | | | - Marina Mione
- IFOM Foundation—FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology, Milan, Italy
| |
Collapse
|
63
|
Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE. Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet 2009; 18:2543-54. [PMID: 19376813 PMCID: PMC2701326 DOI: 10.1093/hmg/ddp186] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The Ras/MAPK pathway is critical for human development and plays a central role in the formation and progression of most cancers. Children born with germ-line mutations in BRAF, MEK1 or MEK2 develop cardio-facio-cutaneous (CFC) syndrome, an autosomal dominant syndrome characterized by a distinctive facial appearance, heart defects, skin and hair abnormalities and mental retardation. CFC syndrome mutations in BRAF promote both kinase-activating and kinase-impaired variants. CFC syndrome has a progressive phenotype, and the availability of clinically active inhibitors of the MAPK pathway prompts the important question as to whether such inhibitors might be therapeutically effective in the treatment of CFC syndrome. To study the developmental effects of CFC mutant alleles in vivo, we have expressed a panel of 28 BRAF and MEK alleles in zebrafish embryos to assess the function of human disease alleles and available chemical inhibitors of this pathway. We find that both kinase-activating and kinase-impaired CFC mutant alleles promote the equivalent developmental outcome when expressed during early development and that treatment of CFC-zebrafish embryos with inhibitors of the FGF-MAPK pathway can restore normal early development. Importantly, we find a developmental window in which treatment with a MEK inhibitor can restore the normal early development of the embryo, without the additional, unwanted developmental effects of the drug.
Collapse
Affiliation(s)
- Corina Anastasaki
- MRC Human Genetics Unit and The University of Edinburgh Institute for Genetics and Molecular Medicine, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
| | - Anne L. Estep
- Department of Pediatrics, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, 2340 Sutter Street, San Francisco, CA 94115, USA
| | - Richard Marais
- Cancer Research UK Centre for Cell and Molecular Biology, Signal Transduction Team, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
| | - Katherine A. Rauen
- Department of Pediatrics, University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, 2340 Sutter Street, San Francisco, CA 94115, USA
| | - E. Elizabeth Patton
- MRC Human Genetics Unit and The University of Edinburgh Institute for Genetics and Molecular Medicine, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
- To whom correspondence should be addressed. Tel: +44 1317773500; Fax: +44 1317773583;
| |
Collapse
|